Yongqi Chen

Dr. Yongqi Chen


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YCYongqi Chen
Yongqi Chen
XZXu Zhongying
Xu Zhongying
LMLiming Mao
Liming Mao
CSCongcong Shen
Congcong Shen
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by immune dysregulation and epidermal barrier dysfunction. The essential oil of Helichrysum (HEO) possesses known anti-inflammatory properties, yet its therapeutic efficacy and underlying mechanisms in AD remain to be fully elucidated. This study aimed to investigate the protective effects of HEO on AD-like skin lesions and to explore its regulatory mechanisms involving the NLRP3 inflammasome and skin barrier proteins. Lipopolysaccharide (LPS)-stimulated HaCaT keratinocytes and RAW264.7 macrophages were treated with HEO to assess cell viability, nitric oxide (NO) production, and the expression of inflammatory mediators (COX-2, iNOS, IL-1β, NLRP3). For in vivo studies, an AD mouse model was induced by repeated application of 1-chloro-2,4-dinitrobenzene (DNCB). Mice were treated topically with HEO, and skin severity scores, ear thickness, and histological changes were evaluated. Expression levels of inflammatory markers and barrier proteins were analyzed via Western blotting and qRT-PCR. Serum levels of cytokines and liver function markers were also measured. Our results showed that, using DNCB-induced AD mouse model, topical application of HEO markedly attenuated dermatitis severity, reduced ear thickness, and suppressed epidermal hyperplasia. Furthermore, HEO treatment alleviated systemic inflammation and liver dysfunction, as evidenced by reduced serum levels of TNF-α, IL-6, AST, ALT, and ALP. Mechanistically, HEO significantly inhibited NO production and downregulated the mRNA and protein expression of COX-2, iNOS, and the NLRP3/IL-1β axis in LPS-stimulated cells. Moreover, it effectively inhibited the activation of NLRP3 inflammasome and altered the expression of skin barrier proteins, Filaggrin and Loricrin, in dorsal tissues of DNCB-treated mice. Together, these data demonstrated that HEO ameliorates AD-like symptoms by suppressing the NLRP3 inflammasome-mediated inflammatory response and restoring epidermal barrier integrity. These findings suggest that HEO is a promising therapeutic candidate for the development of drugs for AD.

7 June 2026 in Genes
Verified
Journal Article
Open access
PDF file
YCYongqi Chen
Yongqi Chen
SJShi Jiyuan
Shi Jiyuan
YRYun Ruan
Yun Ruan
JGJinghan Guan
Jinghan Guan
MYMiaohan Yan
Miaohan Yan
ZLZhaoxiu Liu
Zhaoxiu Liu
Background: Plasticizers, including phthalate esters and phthalate-free alternatives, are widely detected environmental chemicals. Although increasing evidence suggests that plasticizers may disrupt gastrointestinal homeostasis, their potential molecular links with inflammatory gastrointestinal disorders (IGDs) remain unclear. Methods: This study aimed to systematically identify potential molecular targets and pathways linking representative plasticizers with IGDs. An integrative network toxicology framework was applied to investigate four plasticizers, including dimethyl phthalate (DMP), diethyl phthalate (DEP), dioctyl phthalate/di(2-ethylhexyl) phthalate (DOP/DEHP), and acetyl tributyl citrate (ATBC), in relation to Crohn’s disease (CD), ulcerative colitis (UC), esophagitis, and gastritis. Plasticizer- and disease-related targets were collected from public databases, followed by overlapping target screening, protein–protein interaction network analysis, functional enrichment analysis, GEO-based transcriptomic validation, molecular docking, molecular dynamics simulation, and single-cell RNA-seq analysis. Results: Disease-specific candidate targets were identified, including CXCL8 and FN1 for CD, IL1B for UC, MAPK3, FASN, FN1, PPARG, CXCL8, FOS, and HIF1A for esophagitis, and MMP9, TNF, TLR4, IL6, CCR2, IFNG, and PTGS2 for gastritis. Cross-disease analysis further identified plasticizer-associated signature targets, including MMP7 for DMP, HMOX1 and NOS2 for DEP, and LTF and CCL11 for ATBC. Enrichment analysis indicated that these targets were mainly involved in inflammatory, chemokine, MAPK-related, and xenobiotic response pathways. Molecular docking and dynamics simulations suggested stable interactions between selected plasticizers and candidate targets, while single-cell analysis revealed their cell-type-specific expression patterns in epithelial, immune, and stromal compartments. Conclusions: This study provides an exploratory network toxicology framework for identifying potential molecular associations between plasticizer exposure and IGDs. The findings highlight disease-specific and plasticizer-associated candidate targets that may guide future experimental validation and environmental risk assessment.